Abstract: PURPOSE: To summarize the clinical experiences of intralesional injection with a novel of pingyangmycin in the treatment of infantile hemangiomas, and to evaluate its clinical efficacy and safety. METHODS: Clinical data of 203 patients with infantile hemangiomas treated with a novel pingyangmycin injection from April 2016 to April 2017 were retrospectively analyzed. There were 54 males and 149 females. Median age was 10 months ranging 2 months to 6 years old. All 203 cases were classified into 5 types according to the classification methods reported by Liu Xue-jian et al. There were 33 cases of telangiectasis type, 52 of papule type, 59 of plump type, 37 of deep type and 22 of mixed type. There were 56 patients having received other treatments in the early stage, all of them responded poorly (including 38 patients receiving oral propranolol and 18 patients with laser therapy). Pingyangmycin injections were performed at a concentration of 1 mg/mL, and the injections did not stop until the tumors had swelling with slightly pale surface. The dose of pingyangmycin should not exceed 8 mg each time, and patients with large lesions were repeatedly injected at an interal of 1 month. The efficacy was evaluated on a 4-level scale proposed by Achauer et al. SPSS 18.0 software package was used for statistical analysis. RESULTS: After follow-up for 1 to 2 years, there were 167 grade Ⅳ cases, 31 grade Ⅲ cases, 5 grade Ⅱcases and 0 gradeⅠ case. There were significant differences in the efficacy among 5 different types. Papule type showed the best curative effect with a Ⅳ efficacy rate of 94.2%, followed by 93.9% in telangiectasis type, 91.5% in plump type, 51.7% in deep type and 43.4% in mixed type. Three children had mild pigmentation changes in the injection area. Fever occurred in 10 patients, but returned to normal 2 days later. There was no case of high fever, necrosis, allergic shock and pulmonary fibrosis. CONCLUSIONS: Injection of a novel pingyangmycin is recommended in the treatment of infantile hemangioma for its safety and effectiveness, especially for the treatment of lesions of papule, telangiectasis, and plump type.

Key words: Infantile hemangioma, Pingyangmycin, Adverse effects